Figure 14.

Metabolites of sulfasalazine do not prevent metaplasia development after acute gastric damage. (A) Diagram of drug treatments. L635 was administered to C57BL/6J mice for 3 days to induce acute gastric damage. Mice were treated with sulfapyridine or mesalazine daily, 2 days before and throughout L635 administration. Mice were killed 2 hours after the final dose, and stomachs from sulfapyridine + L635–treated (n = 4) and mesalazine + L635–treated (n = 4) C57Bl/6J mice were harvested for histologic analysis. (B) Immunofluorescence staining for metaplastic cell marker CD44v9 (red), mucus granule marker GSII-lectin (green), and zymogenic granule marker GIF (blue). Scale bars: 100 μm. Magnified inset of chief cell region (right). (C) Quantification of CD44v9, GIF, GSII-lectin triple-positive cells per 20× field.